middle.news
How Will Recce’s New Hong Kong Patent Shape Asia’s Anti-Infective Market?
10:22am on Thursday 27th of November, 2025 AEDT
•
Healthcare
Read Story
How Will Recce’s New Hong Kong Patent Shape Asia’s Anti-Infective Market?
10:22am on Thursday 27th of November, 2025 AEDT
Key Points
Hong Kong grants Patent Family 4 for Recce’s anti-infectives, valid until 2041
Patent covers RECCE 327 and RECCE 529 for bacterial and viral infection treatments
Supports multiple administration methods including oral, inhalation, and topical
Strengthens Recce’s position in the growing Hong Kong pharmaceutical market
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE